Onur Yazdan BALÇIK, Ali AYTAÇ, Tugay AVCI, Bilgin DEMİR, Yusuf İLHAN, Gökhan KARAKYA, Atike Pinar ERDOĞAN

Küçük hücreli dışı akciğer kanserinde PBİ, SİYİ ve AİPİ'nin Prognostik Önemi

Amaç: Küçük hücreli dışı akciğer kanseri (KHDAK) en sık görülen ve en çok ölüme sebep olan 3 kanserden birisidir. Mevcut çalışmanın amacı, metastatik KHDAK’lı hastalarda Prognostik Beslenme İndeksi (PBI), sistemik inflamatuvar Yanıt İndeksi (SİYİ), Akciğer İmmün Prognostik İndeksi (AİPİ)’nin prognostik bir öneminin olup olmadığını araştırmaktır. Yöntem: Çalışmamıza 2016-2022 yılları arasında Türkiye'de 5 farklı hastanede patolojik doğrulanmış metastatik KHDAK tanısı almış hastalar dahil edilmiş ve retrospektif olarak incelenmiştir. Bazı hemogram parametreleri ve ldh, albumin gibi biokimyasal parametreler, ayrıca genel sağkalım (GSK) ve progresyonsuz sağkalım (PSK) kaydedilmiştir. Bulgular: Çalışmamıza 297 hasta dahil edilmiştir. Median PSK 5,5 ay iken median GSK 16,03 ay idi. Median GSK PBİ-düşük grup için 14,86 ay, PBİ-yüksek grup için ise 17,2 ay ay idi (p: <0.121). PBİ-düşük grubunun medyan GSK’sı, PBİ-yüksek gruptan daha kısaydı, ancak gruplar arasında istatistiksel olarak anlamlı bir fark yoktu. Median GSK SİYİ-düşük grup için 19,86 ay iken, SİYİ-yüksek grup için ise 14,23 ay idi(p: <0.112). SİRİ-düşük grubunun medyan GSK’sı, SİYİ-yüksek gruptan daha uzundu, ancak gruplar arasında istatistiksel olarak anlamlı bir fark yoktu. Medyan GSK, AİPİ-Düşük grup için 17,76 (%95 GA 16,51 -19,02) ay, AİPİ- orta grup için 15,13 ay, AİPİ-yüksek grup için 13,73 ay (%95 GA 8,05 -19,41) bulundu. AİPİ -Düşük AİPİ -orta ve AİPİ -Yüksek grupları arasında istatistiksel olarak anlamlı bir fark yoktu (p: <0,391). Sonuç: Sonuç olarak PNI ve SIRI daha çok hasta sayısıyla yapılacak spesifik bir hasta grubunda prospektif bir çalışmada KHDAK hastaların prognozunu tahmin etmek için anlamlı çıkabilir.

Anahtar Kelimeler:

: Prognostik Beslenme İndeksi, Systemic İmmün-İnflamasyon İndeksi, Akciğer İmmün Prognostik İndeksi, küçük hücreli dışı akciğer kanseri

Prognostic significance of PNI, SIRI and LIPI in non small-cell lung cancer

Aim: Non-small cell lung cancer (NSCLC) is one of the 3 most common and deadly cancers. The aim of the current study is to investigate whether Prognostic Nutritional Index /PNI), Systemic Immune-Inflammation Index (SIRI), Lung Immune Prognostic Index (LIPI) has a prognostic significance in patients with metastatic NSLCL. Methods: Patients diagnosed with pathologically confirmed metastatic NSCLC in 5 different hospitals in Turkey between 2016-2022 were included in our study and analyzed retrospectively. overall survival (OS) and progression-free survival (PFS) were recorded. Results: The median PFS was 5.50 months, while the median OS was 16.03 months. Median OS was 14.86 months for the PNI-Low group and 17.2 months for the PNI-High group (p: <0.121). The median OS of the PNI-Low group was shorter than the PNI-High group, but there was no statistically significant difference between the groups. Median OS was 19.86 months for the SIRI-Low group and 14.23 months for the SIRI-High group (p: <0.112). Median OS was 17.76, 15.13, 13.73 months for the LIPI-Low, LIPI-intermediate group and LIPI-high group, there was no statistically significant difference between the groups (p: <0.391) Conclusion: In conclusion, PNI and SIRI may be significant in a prospective study in a specific patient group to be performed with a larger number of patients to predict the prognosis of patients with metastatic NSCLC.

Keywords:

Prognostic Nutritional Index, Systemic Immune-Inflammation Index, Lung Immune Prognostic Index, Non-small cell lung cancer,

PDF

___

1. Li S, Zhou K, Wang M, Lin R, Fan J, Che G. Degree of pulmonary fissure completeness can predict postoperative cardiopulmonary complications and length of hospital stay in patients undergoing video-assisted thoracoscopic lobectomy for early-stage lung cancer. Interact Cardiovasc Thorac Surg. 2018;26(1):25-33. doi: 10.1093/icvts/ivx261.
2. Wahbah M, Boroumand N, Castro C, El-Zeky F, Eltorky M. Changing trends in the distribution of the histologic types of lung cancer: a review of 4,439 cases. Ann Diagn Pathol. 2007;11(2):89-96. doi: 10.1016/j.anndiagpath.2006.04.006.
3. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin. 2014;64(1):9-29. doi: 10.3322/caac.21208.
4. Wu HR, Liu CQ, Xu MQ, Xu GW, Xiong R, Li CW, et al. Systematic mediastinal lymph node dissection outcomes and conversion rates of uniportal video-assisted thoracoscopic lobectomy for lung cancer. ANZ J Surg. 2019;89(9):1056-60. doi: 10.1111/ans.15338.
5. Ferrara R, Mezquita L, Texier M, Lahmar J, Audigier-Valette C, Tessonnier L, Mazieres J, Zalcman G, Brosseau S, Le Moulec S, Leroy L, Duchemann B, Lefebvre C, Veillon R, Westeel V, Koscielny S, Champiat S, Ferté C, Planchard D, Remon J, Boucher ME, Gazzah A, Adam J, Bria E, Tortora G, Soria JC, Besse B, Caramella C. Hyperprogressive Disease in Patients With Advanced Non-Small Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or With Single-Agent Chemotherapy. JAMA Oncol. 2018;4(11):1543-52. doi: 10.1001/jamaoncol.2018.3676.
6. Roxburgh CS, McMillan DC. Cancer and systemic inflammation: treat the tumour and treat the host. Br J Cancer. 2014;110(6):1409-12. doi: 10.1038/bjc.2014.90.
7. Atas U, Sozel H, Iltar U, Yucel OK, Salim O, Undar L. The Prognostic Impact of Pretreatment Geriatric Nutritional Risk Index in Patients with Diffuse Large B-Cell Lymphoma. Nutr Cancer. 2023;75(2):591-8. doi: 10.1080/01635581.2022.2142248.
8. Demir H, Demirci A, Eren SK, Beypinar I, Davarcı SE, Baykara M. A New Prognostic Index in Young Breast Cancer Patients. J Coll Physicians Surg Pak. 2022;32(1):86-91. doi: 10.29271/jcpsp.2022.01.86.
9. Wu CY, Lin YH, Lo WC, Cheng PC, Hsu WL, Chen YC, et al. Nutritional status at diagnosis is prognostic for pharyngeal cancer patients: a retrospective study. Eur Arch Otorhinolaryngol. 2022;279(7):3671-8. doi: 10.1007/s00405-021-07222-5.
10. Hong S, Zhou T, Fang W, Xue C, Hu Z, Qin T, et al. The prognostic nutritional index (PNI) predicts overall survival of small-cell lung cancer patients. Tumour Biol. 2015;36(5):3389-97. doi: 10.1007/s13277-014-2973-y.
11. Kucuk A, Ozkan EE, Eskici Oztep S, Mertsoylu H, Pehlivan B, Selek U, et al. The Influence of Systemic Inflammation Response Index on Survival Outcomes of Limited-Stage Small-Cell Lung Cancer Patients Treated with Concurrent Chemoradiotherapy. J Oncol. 2020;2020:8832145. doi: 10.1155/2020/8832145.
12. Hu M, Xu Q, Yang S, Han S, Zhu Y, Lin Q, et al. Pretreatment systemic inflammation response index (SIRI) is an independent predictor of survival in unresectable stage III non-small cell lung cancer treated with chemoradiotherapy: a two-center retrospective study. Ann Transl Med. 2020;8(20):1310. doi: 10.21037/atm-20-6484.
13. Zhang T, Xue W, Wang D, Xu K, Wu L, Wu Y, et al. A validation study on the lung immune prognostic index for prognostic value in patients with locally advanced non-small cell lung cancer. Radiother Oncol. 2021;156:244-250. doi: 10.1016/j.radonc.2020.12.039.
14. Lucijanic M, Veletic I, Rahelic D, Pejsa V, Cicic D, Skelin M, et al. Assessing serum albumin concentration, lymphocyte count and prognostic nutritional index might improve prognostication in patients with myelofibrosis. Wien Klin Wochenschr. 2018;130(3-4):126-33. doi: 10.1007/s00508-018-1318-z.
15. Greten FR, Grivennikov SI. Inflammation and Cancer: Triggers, Mechanisms, and Consequences. Immunity. 2019;51(1):27-41. doi: 10.1016/j.immuni.2019.06.025.
16. Scilla KA, Bentzen SM, Lam VK, Mohindra P, Nichols EM, Vyfhuis MA, et al. Neutrophil-Lymphocyte Ratio Is a Prognostic Marker in Patients with Locally Advanced (Stage IIIA and IIIB) Non-Small Cell Lung Cancer Treated with Combined Modality Therapy. Oncologist. 2017;22(6):737-42. doi: 10.1634/theoncologist.2016-0443.
17. Singhal S, Stadanlick J, Annunziata MJ, Rao AS, Bhojnagarwala PS, O'Brien S, et al. Human tumor-associated monocytes/macrophages and their regulation of T cell responses in early-stage lung cancer. Sci Transl Med. 2019;11(479):eaat1500. doi: 10.1126/scitranslmed.aat1500.
18. Mezquita L, Auclin E, Ferrara R, Charrier M, Remon J, Planchard D, et al. Association of the Lung Immune Prognostic Index With Immune Checkpoint Inhibitor Outcomes in Patients With Advanced Non-Small Cell Lung Cancer. JAMA Oncol. 2018;4(3):351-7. doi: 10.1001/jamaoncol.2017.4771.
19. Wang Z, Wang Y, Zhang X, Zhang T. Pretreatment prognostic nutritional index as a prognostic factor in lung cancer: Review and meta-analysis. Clin Chim Acta. 2018;486:303-10. doi: 10.1016/j.cca.2018.08.030.
20. Sun K, Chen S, Xu J, Li G, He Y. The prognostic significance of the prognostic nutritional index in cancer: a systematic review and meta-analysis. J Cancer Res Clin Oncol. 2014;140(9):1537-49. doi: 10.1007/s00432-014-1714-3.
21. Zhou Q, Su S, You W, Wang T, Ren T, Zhu L. Systemic Inflammation Response Index as a Prognostic Marker in Cancer Patients: A Systematic Review and Meta-Analysis of 38 Cohorts. Dose Response. 2021;19(4):15593258211064744. doi: 10.1177/15593258211064744.
22. Li S, Yang Z, Du H, Zhang W, Che G, Liu L. Novel systemic inflammation response index to predict prognosis after thoracoscopic lung cancer surgery: a propensity score-matching study. ANZ J Surg. 2019;89(11):E507-13. doi: 10.1111/ans.15480.
23. Pierro M, Baldini C, Auclin E, Vincent H, Varga A, Martin Romano P, et al. Predicting Immunotherapy Outcomes in Older Patients with Solid Tumors Using the LIPI Score. Cancers (Basel). 2022;14(20):5078. doi: 10.3390/cancers14205078.
24. Louie AV, Rodrigues G, Yaremko B, Yu E, Dar AR, Dingle B, et al. Management and prognosis in synchronous solitary resected brain metastasis from non-small-cell lung cancer. Clin Lung Cancer. 2009;10(3):174-9. doi: 10.3816/CLC.2009.n.024.
25. Socinski MA, Bondarenko I, Karaseva NA, Makhson AM, Vynnychenko I, Okamoto I, et al. Weekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer: final results of a phase III trial. J Clin Oncol. 2012;30(17):2055-62. doi: 10.1200/JCO.2011.39.5848.
26. Paz-Ares LG, de Marinis F, Dediu M, Thomas M, Pujol JL, Bidoli P, et al. PARAMOUNT: Final overall survival results of the phase III study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer. J Clin Oncol. 2013;31(23):2895-902. doi: 10.1200/JCO.2012.47.1102.